Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07484074 · ClinicalTrials.gov registry record · Phase 1

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

A Phase 1 study of Diabetic Macular Edema (DME) and Neovascular (Wet) Age-Related Macular Degeneration, sponsored by Ollin Biosciences.

Completed
Registry status
Phase 1
Development phase
164
Enrollment target
20
Study locations

NCT07484074: Completed Phase 1 study of Diabetic Macular Edema (DME) and Neovascular (Wet) Age-Related Macular Degeneration, sponsored by Ollin Biosciences.

NCT07484074 is a Phase 1 study of Diabetic Macular Edema (DME) and Neovascular (Wet) Age-Related Macular Degeneration that has completed, run by Ollin Biosciences. The registered enrollment target is 164 participants, below the 341-participant average among 8 other Diabetic Macular Edema (DME) trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07484074, a Phase 1 study of Diabetic Macular Edema (DME) and Neovascular (Wet) Age-Related Macular Degeneration, has completed, sponsored by Ollin Biosciences.

COMPLETED
Registry status
Phase 1
Development phase
164 participants
Enrollment target
20
Study locations

Study Summary

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

Interventions

  • DRUG Faricimab
  • DRUG OLN324

Study Locations (20)

California

  • Glendale, CA - Glendale
  • Pasadena, CA - Pasadena
  • Sacramento, CA - Sacramento
  • Walnut Creek, CA - Walnut Creek

Florida

  • Fort Myers, FL - Fort Myers
  • Saint Petersburg, FL - St. Petersburg
  • Winter Haven, FL - Winter Haven

Texas

  • Abilene, TX - Abilene
  • Arlington, TX - Arlington
  • Austin, TX - Austin

Arizona

  • Phoenix, AZ - Phoenix

Connecticut

  • Waterford, CT - Waterford

Illinois

  • Oak Forest, IL - Oak Forest

Maryland

  • Hagerstown, MD - Hagerstown

Michigan

  • Grand Rapids, MI - Grand Rapids

Trial Details

FieldValue
Enrollment Target 164 participants
Start Date 2025-02-12
Est. Completion 2025-12-09
Phase Phase 1
Ollin Biosciences

1 total trials

What the finished NCT07484074 record still lists

NCT07484074 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 341-participant average among 8 other Diabetic Macular Edema (DME) trials with a reported enrollment target (52% lower).

The record links to 2 conditions, with Diabetic Macular Edema (DME) appearing as the primary indexed condition, and to 2 interventions - of which Faricimab is the first listed.

NCT07484074 names 20 study sites across 13 states, led by California, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT07484074 about?

NCT07484074 is a clinical study titled "A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324". A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

What is the current status of trial NCT07484074?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2025-02-12. Estimated completion is 2025-12-09.

What conditions does trial NCT07484074 study?

This clinical trial studies the following conditions: Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration.

What interventions are being tested in trial NCT07484074?

The interventions under investigation include: Faricimab (DRUG), OLN324 (DRUG).

Who is sponsoring clinical trial NCT07484074?

This trial is sponsored by Ollin Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07484074 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Macular Edema (DME)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07484074's enrollment target sits among peer trials

164 5th of 8 higher than 4 of 8 other Diabetic Macular Edema (DME) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Macular Edema (DME) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04891289 · 164 participants · Phase 2

    Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

  • NCT04893226 · 164 participants · NA

    Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women

  • NCT05270213 · 164 participants · Phase 1

    Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

  • NCT05543681 · 164 participants · Phase 2

    Clinical Trial on Agitation in Alzheimer's Dementia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07484074, the US trial registry maintained by the National Library of Medicine. NCT07484074 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.